ArticleFrontiers in pharmacology2022

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells.

Chao-Yue Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.